ITRM Stock Analysis: Buy, Sell, or Hold?
ITRM - Iterum Therapeutics plc Ordinary Share
$0.04
-0.14 (-79.77%)
▼
5d:
-77.93%
30d:
-84.92%
90d:
-88.88%
WAIT
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Mar 12, 2026
0d
Get Alerted When ITRM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ITRM is down 77.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ITRM is down 77.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ITRM is currently trading at $0.04, which is considered oversold relative to its 30-day fair value range of $0.14 to $0.24.
Technical Outlook: Technically, ITRM is in a strong downtrend. Immediate support is located at $0.03, while resistance sits at $0.18. Short-term momentum is weak, with the stock down 79.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.00 (+25180.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ITRM is in a strong downtrend. Immediate support is located at $0.03, while resistance sits at $0.18. Short-term momentum is weak, with the stock down 79.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.00 (+25180.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.14 -
$0.24
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-79.8%)
- BULLISH: Trading 25180.9% below Wall St target ($9.00)
- WARNING: Recommendation downgraded due to -77.9% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$0.14 -
$0.24
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.03
Resistance Level
$0.18
Current Trend
Strong Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.11
Wall Street Target
$9.00
(+25180.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: March 30, 2026 8:28 AM ET
Data refreshes hourly during market hours. Next update: 9:28 AM
Data refreshes hourly during market hours. Next update: 9:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ITRM showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Michael W Dunne
BUY
6000 shares
2025-11-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 42 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 54 HOLD |
